PsiOxus Information

PsiOxus aims to be the world’s leading company in tumour re-programming, delivering medicines of value to patients with cancer. PsiOxus is a clinical stage oncology company pioneering systemic immune oncology products that drive sustained reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy. Our validated T-SIGn® vector platform can deliver multiple transgene payloads that re-program both primary and metastatic tumors. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer. Find our more about us at www.psioxus.com